VVUS - VIVUS, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.735
-0.036 (-4.67%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.771
Open0.756
Bid0.596 x 900
Ask0.860 x 800
Day's Range0.730 - 0.783
52 Week Range0.330 - 1.260
Volume450,755
Avg. Volume1,411,041
Market Cap77.95M
Beta0.51
PE Ratio (TTM)N/A
EPS (TTM)-0.380
Earnings DateAug 1, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • VIVUS' PAH Candidate Data Positive in Early Stage Study
    Zacks6 days ago

    VIVUS' PAH Candidate Data Positive in Early Stage Study

    VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.

  • VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session
    Zacks6 days ago

    VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session

    VIVUS (VVUS) was a big mover last session, as the company saw its shares rise more than 10% on the day, amid huge volumes.

  • GlobeNewswire7 days ago

    VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106

    -Favorable pharmacokinetic results add to body of data supporting continued development in the treatment of pulmonary arterial hypertension-. CAMPBELL, Calif., July 10, 2018-- VIVUS, Inc., a biopharmaceutical ...

  • 3 Biotech Stocks Up in the Past Month on Industry Turnaround
    InvestorPlacelast month

    3 Biotech Stocks Up in the Past Month on Industry Turnaround

    After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.

  • Benzingalast month

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! NANO DIMENSION/S ADR (NASDAQ: NNDM ) stock was trading ...

  • Can The Uptrend Continue for VIVUS (VVUS)?
    Zackslast month

    Can The Uptrend Continue for VIVUS (VVUS)?

    Investors certainly have to be happy with VIVUS, Inc. (VVUS) and its short term performance

  • GlobeNewswirelast month

    VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of PANCREAZE® and Previously Announced Financing Transaction

    VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced that it has met the closing conditions, including Hart-Scott-Rodino review, related to the Company’s previously announced acquisition of U.S. and Canadian rights to PANCREAZE® (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) from Janssen Pharmaceuticals, Inc. (Janssen) for $135 million. Concurrently, VIVUS completed its previously announced financing agreement with Athyrium Capital Management, L.P. (Athyrium). “The restructuring of a portion of our debt coupled with the acquisition of a cash flow generating asset, PANCREAZE, will move VIVUS towards our goal of becoming an operating profit generating specialty pharmaceutical company.  The PANCREAZE transaction fits a well-defined strategy of acquiring assets utilizing VIVUS’ improving operational and financial discipline as a base platform,” said John Amos, Chief Executive Officer at VIVUS.

  • 3 Biotech Stocks Up in the Past Month on Industry Turnaround
    Zackslast month

    3 Biotech Stocks Up in the Past Month on Industry Turnaround

    We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks

    Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.

  • VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher
    Zacks2 months ago

    VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher

    VIVUS (VVUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

  • Vivus Stock Rose 60% Last Week
    Market Realist2 months ago

    Vivus Stock Rose 60% Last Week

    Vivus (VVUS) rose 60% between May 11 and May 18. Headquartered in Cambell, California, Vivus is a fast-growing healthcare company focused on the development of innovative therapies for obesity, sexual health, and sleep. In May 2018, Vivus entered an agreement with Johnson & Johnson (JNJ) to acquire all product rights of Janssen Pharmaceuticals’ Pancreaze in the United States.

  • ACCESSWIRE2 months ago

    Biotech CEO Presents: Merck’s $500M Pain, Our Potential Gain

    Synergy Pharma's valuation peaked after data suggested its CIC treatment could challenge Ironwood's Lizness; Vivus soared on potential to beat weight-loss drugs with significant adverse effects Bellus ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and VIVUS

    NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Eleven Biotherapeutics and VIVUS, Inc. were two biotech stocks to see big gains in Wednesday's trading session. VIVUS reported first quarter earnings earlier this month and recently announced an agreement to acquire all rights to Janssen's exocrine pancreatic insufficiency drug, pancreaze, in the United States and Canada. Janssen is a subsidiary of Johnson & Johnson.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of VVUS earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 Vivus Inc Earnings Call

  • VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
    Zacks2 months ago

    VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters

    VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.

  • Associated Press2 months ago

    Vivus: 1Q Earnings Snapshot

    The Campbell, California-based company said it had a loss of 10 cents per share. The biopharmaceutical company posted revenue of $11.9 million in the period. In the final minutes of trading on Tuesday, ...

  • GlobeNewswire2 months ago

    VIVUS Reports First Quarter 2018 Financial Results

    Company provides business update on PANCREAZE ® acquisition, new Athyrium debt line and new management. Company to host conference call today at 4:30pm ET. CAMPBELL, Calif., May 08, 2018-- VIVUS, Inc., ...

  • GlobeNewswire2 months ago

    VIVUS Announces Date of 2018 Annual Meeting

    Pursuant to Rule 14a‑8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), stockholders may present proper proposals for inclusion in the 2018 Proxy Statement and for consideration at the Company’s 2018 Annual Meeting.  To be eligible for inclusion in the 2018 Proxy Statement, a proposal must be received by the Company no later than May 21, 2018 and must otherwise comply with Rule 14a‑8. In addition, under the Company’s Amended and Restated Bylaws, as further amended, in order to nominate a director or bring any other business before the stockholders at the 2018 Annual Meeting that will not be included in the 2018 Proxy Statement, the proposal must be received by the Company’s Corporate Secretary on or between May 10, 2018 and June 9, 2018.

  • ACCESSWIRE2 months ago

    VIVUS, Inc., New Team, New Acquisition Agreement, New Product, Analysts Review

    NEW YORK, NY / ACCESSWIRE / May 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on VIVUS, Inc. (VVUS) is a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health. VIVUS has announced new management members and new initiatives over the past few trading days. On April 30, 2018 VVUS announced the addition of three executives to the Company's senior leadership team.

  • ACCESSWIRE2 months ago

    Blog Exposure - VIVUS to Acquire Janssen Pharma’s PANCREAZE(R) Capsules in the United States and Canada

    LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on VIVUS, Inc. (NASDAQ: VVUS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VVUS as the Company's latest news hit the wire. On May 01, 2018, the Company announced that it has inked an agreement to acquire all of the product rights for Janssen Pharmaceuticals, Inc.'s PANCREAZE® (pancrelipase) Delayed-Release Capsules in the United States and Canada, for approximately $135 million.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Avinger and VIVUS

    NEW YORK, NY / ACCESSWIRE / May 2, 2018 / Positive developments sent shares of both Avinger and VIVUS higher on Tuesday. Avinger announced that its next generationPantheris Lumivascular atherectomy system with extended nosecone was featured in a live case transmission at Charing Cross International Symposium 2018. VIVUS announced that it has entered into a definitive agreement for the acquisition of PANCREAZE.

  • GlobeNewswire3 months ago

    VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE®

    CAMPBELL, Calif., May 01, 2018-- VIVUS, Inc., a biopharmaceutical company, today announced that it has entered into a definitive agreement to acquire all product rights for PANCREAZE ® Delayed-Release ...

  • GlobeNewswire3 months ago

    VIVUS Restructures Debt and Gains Access to New Capital

    VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company and Athyrium Capital Management L.P. (“Athyrium”), a specialized asset management company focused on investment opportunities in the global healthcare sector, today announced an agreement to restructure a portion of VIVUS’ corporate debt while raising new funds through the issuance of debt securities to investment funds managed by Athyrium.

  • Marketwired3 months ago

    VIVUS Strengthens Executive Leadership Team

    VIVUS,Inc. , a biopharmaceutical company, today announced the addition of three executives to the Company's senior leadership team. John Amos has joined as the Company's new Chief Executive Officer and ...

  • Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018
    Market Realist3 months ago

    Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY (year-over-year) growth in local currency.